Altogether, these findings highlight the immunoregulatory role of CD73 in the development of HNSCC and we propose that CD73 may prove to be a promising immunotherapeutic target for the treatment of HNSCC.
The highest level of CD39/CD73 ectoenzymes and of adenosine production was found in CD3<sup>(-)</sup> exosomes in patients with the stages III/IV HNSCCs).
In all, we reported, for the first time, that MiR-422a and its target CD73 are involved in early loco(regional) recurrence of HNSCC tumors and are new targets for personalized medicine.